, Volume 48, Issue 3, pp 978–984 | Cite as

Natural course of hypogonadism diagnosed during hospitalization in aged male patients

  • P. IglesiasEmail author
  • F. Prado
  • A. Muñoz
  • M. T. Guerrero
  • M. C. Macías
  • E. Ridruejo
  • P. Tajada
  • C. García-Arévalo
  • J. J. Díez
Original Article


Our aim was to assess short-term natural course of hypogonadism diagnosed during hospitalization for acute disease in aged male patients after discharge. A group of 43 hypogonadal males, aged 86.7 ± 5.7 year, was studied. Serum concentrations of testosterone (T) and gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) were measured in every patient both at admission and one month after discharge. Mean serum T at entry was 115.4 ± 48.0 ng/dl. Hypogonadism was hyper-, hypo-, and normogonadotropic in 20 (46.5 %), 20 (46.5 %), and 3 (7.0 %) patients, respectively. One month after discharge serum T concentrations increased significantly (230.9 ± 135.6 ng/dl, p < 0.001). At this point, more than half of the patients (n = 27, 62.8 %) showed normal serum T concentrations. Both gonadotropins, FSH (p < 0.001), and LH (p = 0.04) also increased one month after discharge. Approximately, half of the patients (13, 48.1 %) who normalized serum T concentrations also showed normal serum gonadotropin concentrations. Patients who normalized their serum T concentrations one month after discharge showed significantly higher baseline values of T (134.7 ± 33.9 ng/dl) than those who persisted with hypogonadism (n = 16, 32.7 %; 82.8 ± 51.6 ng/dl, p < 0.001). Lastly, serum T was the only independent predictor for achieving eugonadal status (OR 1.030; CI 95 %, 1.010–1.050; p < 0.001). In conclusion, about 63 % of aged patients hospitalized for acute illness with hypogonadism discovered during hospitalization spontaneously normalize their serum T concentrations one month after discharge. Serum gonadotropin concentrations also increased after discharge. Serum T levels at admission was an independent predictor for the normalization of serum T concentrations.


Testosterone Elderly Hypogonadism Gonadotropins Spontaneous recovery 



This study was funded by the Junta de Castilla y León (Spain), Consejería de Sanidad Proyectos de Investigación en Biomedicina, Biotecnología y Ciencias de la Salud. Expediente nº GRS 393/A/09.

Conflict of interest

None declared.


  1. 1.
    I. Huhtaniemi, Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment. Asian J. Androl. 16, 192–202 (2014)CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    G. Vitale, S. Salvioli, C. Franceschi, Oxidative stress and the ageing endocrine system. Nat. Rev. Endocrinol. 9, 228–240 (2013)CrossRefPubMedGoogle Scholar
  3. 3.
    J.L. Tostain, F. Blanc, Testosterone deficiency: a common, unrecognized syndrome. Nat. Clin. Pract. Urol. 5, 388–396 (2008)CrossRefPubMedGoogle Scholar
  4. 4.
    S.M. Harman, E.J. Metter, J.D. Tobin, J. Pearson, M.R. Blackman, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J. Clin. Endocrinol. Metab. 86, 724–731 (2001)CrossRefPubMedGoogle Scholar
  5. 5.
    A. Vermeulen, J.M. Kaufman, Diagnosis of hypogonadism in the aging male. Aging Male 5, 170–176 (2002)CrossRefPubMedGoogle Scholar
  6. 6.
    C.A. Allan, R.I. McLachlan, Age-related changes in testosterone and the role of replacement therapy in older men. Clin. Endocrinol (Oxf) 60, 653–670 (2004)CrossRefGoogle Scholar
  7. 7.
    A.B. Araujo, A.B. O’Donnell, D.J. Brambilla, W.B. Simpson, C. Longcope, A.M. Matsumoto, J.B. McKinlay, Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metab. 89, 5920–5926 (2004)CrossRefPubMedGoogle Scholar
  8. 8.
    A.B. Araujo, G.R. Esche, V. Kupelian, A.B. O’Donnell, T.G. Travison, R.E. Williams, R.V. Clark, J.B. McKinlay, Prevalence of symptomatic androgen deficiency in men. J. Clin. Endocrinol. Metab. 92, 4241–4247 (2007)CrossRefPubMedGoogle Scholar
  9. 9.
    C. Wang, E. Nieschlag, R. Swerdloff, H.M. Behre, W.J. Hellstrom, L.J. Gooren, J.M. Kaufman, J.J. Legros, B. Lunenfeld, A. Morales, J.E. Morley, C. Schulman, I.M. Thompson, W. Weidner, F.C. Wu, Investigation, treatment and monitoring of late-onset hypogonadism in males: iSA, ISSAM, EAU, EAA and ASA recommendations. Eur. J. Endocrinol. 159, 507–514 (2008)CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    F.C. Wu, A. Tajar, S.R. Pye, A.J. Silman, J.D. Finn, T.W. O’Neill, G. Bartfai, F. Casanueva, G. Forti, A. Giwercman, I.T. Huhtaniemi, K. Kula, M. Punab, S. Boonen, D. Vanderschueren, European Male Aging Study Group, Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: The European Male Aging Study. J. Clin. Endocrinol. Metab. 93, 2737–2745 (2008)CrossRefPubMedGoogle Scholar
  11. 11.
    K. Venkat, M. Desai, M.M. Arora, P. Singh, M.I. Khatkhatay, Age-related changes in sex steroid levels influence bone mineral density in healthy indian men. Osteoporos. Int. 20, 955–962 (2009)CrossRefPubMedGoogle Scholar
  12. 12.
    P. Iglesias, F. Prado, M.C. Macias, M.T. Guerrero, A. Munoz, E. Ridruejo, P. Tajada, C. García-Arévalo, J.J. Díez, Hypogonadism in aged hospitalized male patients prevalence and clinical outcome. J. Endocrinol. Invest. 37, 135–141 (2014)CrossRefPubMedGoogle Scholar
  13. 13.
    A.M. Matsumoto, Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. A Biol. Sci. Med. Sci. 57, M76–M99 (2002)CrossRefPubMedGoogle Scholar
  14. 14.
    T.G. Travison, A.B. Araujo, V. Kupelian, A.B. O’Donnell, J.B. McKinlay, The relative contributions of aging, health, and lifestyle factors to serum testosterone decline in men. J. Clin. Endocrinol. Metab. 92, 549–555 (2007)CrossRefPubMedGoogle Scholar
  15. 15.
    M. Volterrani, G. Rosano, F. Iellamo, Testosterone and heart failure. Endocrine 42, 272–277 (2012)CrossRefPubMedGoogle Scholar
  16. 16.
    R.A. Adler, Osteoporosis in men: recent progress. Endocrine 44, 40–46 (2013)CrossRefPubMedGoogle Scholar
  17. 17.
    A. Lehtonen, R. Huupponen, J. Tuomilehto, S. Lavonius, S. Arve, H. Isoaho, I. Huhtaniemi, R. Tilvis, Serum testosterone but not leptin predicts mortality in elderly men. Age Ageing 37, 461–464 (2008)CrossRefPubMedGoogle Scholar
  18. 18.
    A. Tivesten, L. Vandenput, F. Labrie, M.K. Karlsson, O. Ljunggren, D. Mellström, C. Ohlsson, Low serum testosterone and estradiol predict mortality in elderly men. J. Clin. Endocrinol. Metab. 94, 2482–2488 (2009)CrossRefPubMedGoogle Scholar
  19. 19.
    B.B. Yeap, Androgens and cardiovascular disease. Curr. Opin. Endocrinol. Diabetes Obes. 17, 269–276 (2010)CrossRefPubMedGoogle Scholar
  20. 20.
    G. Corona, G. Rastrelli, M. Monami, A. Guay, J. Buvat, A. Sforza, G. Forti, E. Mannucci, M. Maggi, Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur. J. Endocrinol. 165, 687–701 (2011)CrossRefPubMedGoogle Scholar
  21. 21.
    G. Tirabassi, A. Gioia, L. Giovannini, M. Boscaro, G. Corona, A. Carpi et al., Testosterone and cardiovascular risk. Intern. Emerg. Med. 8, S65–S69 (2013)CrossRefPubMedGoogle Scholar
  22. 22.
    A. Vermeulen, L. Verdonck, J.M. Kaufman, A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666–3672 (1999)CrossRefPubMedGoogle Scholar
  23. 23.
    P.D. Woolf, R.W. Hamill, J.V. McDonald, L.A. Lee, M. Kelly, Transient hypogonadotropic hypogonadism caused by critical illness. J. Clin. Endocrinol. Metab. 60, 444–450 (1985)CrossRefPubMedGoogle Scholar
  24. 24.
    D.I. Spratt, S.T. Bigos, I. Beitins, P. Cox, C. Longcope, J. Orav, Both hyper- and hypogonadotropic hypogonadism occur transiently in acute illness: bio- and immunoactive gonadotropins. J. Clin. Endocrinol. Metab. 75, 1562–1570 (1992)PubMedGoogle Scholar
  25. 25.
    D.M. Nierman, J.I. Mechanick, Hypotestosteronemia in chronically critically ill men. Crit. Care Med. 27, 2418–2421 (1999)CrossRefPubMedGoogle Scholar
  26. 26.
    V. Muraleedharan, H. Marsh, D. Kapoor, K.S. Channer, T.H. Jones, Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur. J. Endocrinol. 169, 725–733 (2013)CrossRefPubMedGoogle Scholar
  27. 27.
    A. Tsujimura, The relationship between testosterone deficiency and men’s health. World J. Mens Health. 31, 126–135 (2013)CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    T. Yasui, J. Tomita, Y. Miyatani, M. Yamada, H. Uemura, M. Irahara, M. Arai, N. Kojimahara, R. Okabe, Y. Ishii, S. Tashiro, H. Sato, Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin. Chim. Acta 386, 69–75 (2007)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • P. Iglesias
    • 1
    Email author
  • F. Prado
    • 2
  • A. Muñoz
    • 2
  • M. T. Guerrero
    • 2
  • M. C. Macías
    • 2
  • E. Ridruejo
    • 2
  • P. Tajada
    • 3
  • C. García-Arévalo
    • 3
  • J. J. Díez
    • 1
  1. 1.Department of EndocrinologyHospital Ramón y CajalMadridSpain
  2. 2.Departments of GeriatricsHospital GeneralSegoviaSpain
  3. 3.Departments of BiochemistryHospital GeneralSegoviaSpain

Personalised recommendations